Time period What may be noticeable What the evidence supports Weeks 1-4 Satiety, appetite changes, nausea, bowel changes, early scale movement Early tolerability period, not the main efficacy endpoint window Weeks 4-12 More consistent appetite suppression and early weight trend Direction of response may become clearer, but individual variance is high Weeks 12-24 Clinically meaningful separation becomes easier to evaluate Phase 2 primary endpoint at 24 weeks showed dose-dependent weight loss Weeks 24-48 Major body-weight reduction window in Phase 2 48-week Phase 2 secondary endpoint showed the largest published Phase 2 changes Weeks 68-104 Longer-term Phase 3 and extension outcomes TRIUMPH program endpoints measure durability over longer windows Weeks 1-4: Early Signals, Not Final Results The first few weeks are usually the wrong window for judging full retatrutide results
Ive got you
GHK-Cu Compared to Other Research Peptides and Actives GHK-Cu vs BPC-157 (Research Context) GHK-Cu vs Retinol (Mechanism Comparison) Retinol acts via nuclear retinoic acid receptors and modifies transcription of keratinocyte differentiation and dermal remodeling genes
Birth control, antidepressants, insulin, blood thinners they all matter
Safety Considerations While semaglutide and vitamin D are generally safe when used as prescribed, combining them requires careful planning under medical supervision
